Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell adhesion molecule 3 (CADM3) is a neural-specific, immunoglobulin superfamily cell adhesion protein encoded by the CADM3 gene. It mediates calcium-independent cell-cell adhesion by forming both homodimers (with itself) and heterodimers (with related proteins such as IGSF4, NECTIN1, and NECTIN3). CADM3 is predominantly expressed in the brain where it participates in the formation and stabilization of neuronal connections, playing critical roles in both sensory and motor neurons. It acts as a negative regulator of Schwann cell myelination in the peripheral nervous system. Loss or reduced expression of CADM3 has been linked to the development of certain cancers (notably glioma), suggesting it functions as a tumor suppressor. Mutations in CADM3 are also associated with neurological diseases, including certain forms of Charcot-Marie-Tooth disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell adhesion molecule 3 (CADM3).